Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (3444)	4/17/2001 11:26:16 PM
From: Biomaven	Respond to of 52153

Interesting NYT article today on Leroy Hood: Approaching Biology From a Different Angle SCIENTIST AT WORK / Leroy Hood By ANDREW POLLACK SEATTLE — It was a major coup in 1991 when the University of Washington, with a $12 million grant from Microsoft's chairman, William H. Gates, lured Dr. Leroy Hood to create and head a molecular biotechnology department. Dr. Hood, after all, was, and still is, a biotechnology superstar. In the 1980's, while at the California Institute of Technology, he led the team that invented the DNA sequencer, the machine that made the Human Genome Project possible. At the news conference in February announcing the publication of the genome papers, Dr. Francis S. Collins, director of the National Human Genome Research Institute, singled out Dr. Hood, saying, "We would not be here today if not for the innovation in technology." Dr. Hood has also helped show how the immune system creates its arsenal of antibodies. And he has helped start more than half a dozen companies, including Amgen, the largest biotech company, and Applied Biosystems, the leading maker of genetic analysis equipment. A little more than a year ago, Dr. Hood quit the university and delivered a stinging message. The university, he said, and universities in general, are unfit for the new age of biology. <snip> nytimes.com

To: Jibacoa who wrote (3444)	4/18/2001 12:50:24 PM
From: Jibacoa	Read Replies (1) \| Respond to of 52153

ORCH:Is doing better today. Up 17.85% on volume of 228,400 with B/A of 15/1 at present. They have reported a few deals in the last several months with BMY,LLY, PKI, PHA,EXEL,AZN among others: yahoo.marketguide.com ORCH together with SQNM, ABI and AFFX were mentioned in the INFORMATICS category in Red Herrings note about "bottom fishing" in the depths of biotech: redherring.com At any rate, I liked ORCH chart and bought some in spite of their large "loss per share" for the last 12 months.<g> It had an up-gap today, before the news of the FED's 1/2 point cut: siliconinvestor.com Bernard